Alterations in erythrocyte fatty acid composition in preclinical Alzheimer’s disease

Abstract Brain and blood fatty acids (FA) are altered in Alzheimer’s disease and cognitively impaired individuals, however, FA alterations in the preclinical phase, prior to cognitive impairment have not been investigated previously. The current study therefore evaluated erythrocyte FA in cognitivel...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kathryn Goozee, Pratishtha Chatterjee, Ian James, Kaikai Shen, Hamid R. Sohrabi, Prita R. Asih, Preeti Dave, Bethany Ball, Candice ManYan, Kevin Taddei, Roger Chung, Manohar L. Garg, Ralph N. Martins
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/5fb81ae1caec4113ad4d2005ed84ba84
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5fb81ae1caec4113ad4d2005ed84ba84
record_format	dspace
spelling	oai:doaj.org-article:5fb81ae1caec4113ad4d2005ed84ba842021-12-02T16:06:28ZAlterations in erythrocyte fatty acid composition in preclinical Alzheimer’s disease10.1038/s41598-017-00751-22045-2322https://doaj.org/article/5fb81ae1caec4113ad4d2005ed84ba842017-04-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-00751-2https://doaj.org/toc/2045-2322Abstract Brain and blood fatty acids (FA) are altered in Alzheimer’s disease and cognitively impaired individuals, however, FA alterations in the preclinical phase, prior to cognitive impairment have not been investigated previously. The current study therefore evaluated erythrocyte FA in cognitively normal elderly participants aged 65–90 years via trans-methylation followed by gas chromatography. The neocortical beta-amyloid load (NAL) measured via positron emission tomography (PET) using ligand 18F-Florbetaben, was employed to categorise participants as low NAL (standard uptake value ratio; SUVR < 1.35, N = 65) and high NAL or preclinical AD (SUVR ≥ 1.35, N = 35) wherein, linear models were employed to compare FA compositions between the two groups. Increased arachidonic acid (AA, p < 0.05) and decreased docosapentaenoic acid (DPA, p < 0.05) were observed in high NAL. To differentiate low from high NAL, the area under the curve (AUC) generated from a ‘base model’ comprising age, gender, APOEε4 and education (AUC = 0.794) was outperformed by base model + AA:DPA (AUC = 0.836). Our findings suggest that specific alterations in erythrocyte FA composition occur very early in the disease pathogenic trajectory, prior to cognitive impairment. As erythrocyte FA levels are reflective of tissue FA, these alterations may provide insight into the pathogenic mechanism(s) of the disease and may highlight potential early diagnostic markers and therapeutic targets.Kathryn GoozeePratishtha ChatterjeeIan JamesKaikai ShenHamid R. SohrabiPrita R. AsihPreeti DaveBethany BallCandice ManYanKevin TaddeiRoger ChungManohar L. GargRalph N. MartinsNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-9 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Kathryn Goozee Pratishtha Chatterjee Ian James Kaikai Shen Hamid R. Sohrabi Prita R. Asih Preeti Dave Bethany Ball Candice ManYan Kevin Taddei Roger Chung Manohar L. Garg Ralph N. Martins Alterations in erythrocyte fatty acid composition in preclinical Alzheimer’s disease
description	Abstract Brain and blood fatty acids (FA) are altered in Alzheimer’s disease and cognitively impaired individuals, however, FA alterations in the preclinical phase, prior to cognitive impairment have not been investigated previously. The current study therefore evaluated erythrocyte FA in cognitively normal elderly participants aged 65–90 years via trans-methylation followed by gas chromatography. The neocortical beta-amyloid load (NAL) measured via positron emission tomography (PET) using ligand 18F-Florbetaben, was employed to categorise participants as low NAL (standard uptake value ratio; SUVR < 1.35, N = 65) and high NAL or preclinical AD (SUVR ≥ 1.35, N = 35) wherein, linear models were employed to compare FA compositions between the two groups. Increased arachidonic acid (AA, p < 0.05) and decreased docosapentaenoic acid (DPA, p < 0.05) were observed in high NAL. To differentiate low from high NAL, the area under the curve (AUC) generated from a ‘base model’ comprising age, gender, APOEε4 and education (AUC = 0.794) was outperformed by base model + AA:DPA (AUC = 0.836). Our findings suggest that specific alterations in erythrocyte FA composition occur very early in the disease pathogenic trajectory, prior to cognitive impairment. As erythrocyte FA levels are reflective of tissue FA, these alterations may provide insight into the pathogenic mechanism(s) of the disease and may highlight potential early diagnostic markers and therapeutic targets.
format	article
author	Kathryn Goozee Pratishtha Chatterjee Ian James Kaikai Shen Hamid R. Sohrabi Prita R. Asih Preeti Dave Bethany Ball Candice ManYan Kevin Taddei Roger Chung Manohar L. Garg Ralph N. Martins
author_facet	Kathryn Goozee Pratishtha Chatterjee Ian James Kaikai Shen Hamid R. Sohrabi Prita R. Asih Preeti Dave Bethany Ball Candice ManYan Kevin Taddei Roger Chung Manohar L. Garg Ralph N. Martins
author_sort	Kathryn Goozee
title	Alterations in erythrocyte fatty acid composition in preclinical Alzheimer’s disease
title_short	Alterations in erythrocyte fatty acid composition in preclinical Alzheimer’s disease
title_full	Alterations in erythrocyte fatty acid composition in preclinical Alzheimer’s disease
title_fullStr	Alterations in erythrocyte fatty acid composition in preclinical Alzheimer’s disease
title_full_unstemmed	Alterations in erythrocyte fatty acid composition in preclinical Alzheimer’s disease
title_sort	alterations in erythrocyte fatty acid composition in preclinical alzheimer’s disease
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/5fb81ae1caec4113ad4d2005ed84ba84
work_keys_str_mv	AT kathryngoozee alterationsinerythrocytefattyacidcompositioninpreclinicalalzheimersdisease AT pratishthachatterjee alterationsinerythrocytefattyacidcompositioninpreclinicalalzheimersdisease AT ianjames alterationsinerythrocytefattyacidcompositioninpreclinicalalzheimersdisease AT kaikaishen alterationsinerythrocytefattyacidcompositioninpreclinicalalzheimersdisease AT hamidrsohrabi alterationsinerythrocytefattyacidcompositioninpreclinicalalzheimersdisease AT pritarasih alterationsinerythrocytefattyacidcompositioninpreclinicalalzheimersdisease AT preetidave alterationsinerythrocytefattyacidcompositioninpreclinicalalzheimersdisease AT bethanyball alterationsinerythrocytefattyacidcompositioninpreclinicalalzheimersdisease AT candicemanyan alterationsinerythrocytefattyacidcompositioninpreclinicalalzheimersdisease AT kevintaddei alterationsinerythrocytefattyacidcompositioninpreclinicalalzheimersdisease AT rogerchung alterationsinerythrocytefattyacidcompositioninpreclinicalalzheimersdisease AT manoharlgarg alterationsinerythrocytefattyacidcompositioninpreclinicalalzheimersdisease AT ralphnmartins alterationsinerythrocytefattyacidcompositioninpreclinicalalzheimersdisease
_version_	1718384962985525248

Alterations in erythrocyte fatty acid composition in preclinical Alzheimer’s disease

Ejemplares similares